Eli Lilly's stock price has steadily risen since the beginning of the year. How much a $1,000 investment made one, five and 10 years ago would be worth now.
"We just see unbelievable demand, and we're not even trying that hard to promote this drug," Eli Lilly CEO David Ricks told CNBCThursday. "What you're seeing is just consumer organic demand here as we've shipped more product, as we bring more supply online in the United States."latest data from the Centers for Disease Control and Prevention
The demand for weight loss drugs is on the rise around the world, too. The global market for obesity medication is expected to hit $105 billion in 2030, according toHow much you'd have if you invested $1,000 in Eli Lilly An index fund aims to mirror the performance of a market index such as the S&P 500, which tracks the stock performance of around 500 large U.S. companies. When you invest in an S&P 500 ETF, for instance, your dollars are actually spread across a wide range of top-performing companies, such as Eli Lilly, Apple and Nvidia.
Pharmaceuticals David A. Ricks Eli Lilly And Co Personal Investing Personal Finance Weight Management
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Mounjaro, Zepbound pour money into Eli Lilly, fueling a better-than-expected second quarterEli Lilly blew past second-quarter expectations with the diabetes treatment Mounjaro and its weight loss counterpart Zepbound funneling more than $4 billion in sales to the drugmaker. Lilly also hiked its forecast for the year well beyond Wall Street expectations as newer drugs like Zepbound built momentum.
Read more »
Mounjaro, Zepbound pour money into Eli Lilly, fueling a better-than-expected second quarterMounjaro sales more than tripled in the quarter to nearly $3.1 billion. Zepbound, which is made from the same molecule, brought in $1.2 billion two quarters after regulators approved the drug.
Read more »
Mounjaro, Zepbound pour money into Eli Lilly, fueling a better-than-expected second quarterli Lilly blew past second-quarter expectations with the diabetes treatment Mounjaro and its weight loss counterpart Zepbound funneling more than $4 billion in sales to the drugmaker.
Read more »
Mounjaro, Zepbound pour money into Eli Lilly, fueling a better-than-expected second quarterli Lilly blew past second-quarter expectations with the diabetes treatment Mounjaro and its weight loss counterpart Zepbound funneling more than $4 billion in sales to the drugmaker.
Read more »
Eli Lilly's blowout quarter should quiet investor concerns about the stockShares of the drugmaker jumped about 8% in Thursday trading after easily beating earnings expectations.
Read more »
Stocks making the biggest moves midday: Eli Lilly, Under Armour, Warner Bros. Discovery and moreThese are the stocks posting the largest moves in midday trading.
Read more »